227 related articles for article (PubMed ID: 12110142)
1. Signaling crosstalk between RANKL and interferons in osteoclast differentiation.
Takayanagi H; Kim S; Taniguchi T
Arthritis Res; 2002; 4 Suppl 3(Suppl 3):S227-32. PubMed ID: 12110142
[TBL] [Abstract][Full Text] [Related]
2. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.
Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T
Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
[TBL] [Abstract][Full Text] [Related]
4. Interplay between interferon and other cytokine systems in bone metabolism.
Takayanagi H; Sato K; Takaoka A; Taniguchi T
Immunol Rev; 2005 Dec; 208():181-93. PubMed ID: 16313349
[TBL] [Abstract][Full Text] [Related]
5. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta.
Takayanagi H; Kim S; Matsuo K; Suzuki H; Suzuki T; Sato K; Yokochi T; Oda H; Nakamura K; Ida N; Wagner EF; Taniguchi T
Nature; 2002 Apr; 416(6882):744-9. PubMed ID: 11961557
[TBL] [Abstract][Full Text] [Related]
6. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis.
Kanazawa K; Kudo A
J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857
[TBL] [Abstract][Full Text] [Related]
7. RANKing intracellular signaling in osteoclasts.
Feng X
IUBMB Life; 2005 Jun; 57(6):389-95. PubMed ID: 16012047
[TBL] [Abstract][Full Text] [Related]
8. FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner.
Bai S; Kitaura H; Zhao H; Chen J; Müller JM; Schüle R; Darnay B; Novack DV; Ross FP; Teitelbaum SL
J Clin Invest; 2005 Oct; 115(10):2742-51. PubMed ID: 16184196
[TBL] [Abstract][Full Text] [Related]
9. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation.
Hayashi T; Kaneda T; Toyama Y; Kumegawa M; Hakeda Y
J Biol Chem; 2002 Aug; 277(31):27880-6. PubMed ID: 12023971
[TBL] [Abstract][Full Text] [Related]
10. [Prospects of treatment using interferon for bone diseases].
Iba K; Takada J; Yamashita T
Nihon Rinsho; 2006 Jul; 64(7):1275-80. PubMed ID: 16838644
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic insight into osteoclast differentiation in osteoimmunology.
Takayanagi H
J Mol Med (Berl); 2005 Mar; 83(3):170-9. PubMed ID: 15776286
[TBL] [Abstract][Full Text] [Related]
12. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
13. RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T; Nakashima T; Hiroshi N; Penninger JM
Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
[TBL] [Abstract][Full Text] [Related]
14. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
15. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
16. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
17. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
19. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.
Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L
J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]